<h4>Introduction</h4>Spironolactone (SPI), a mineralocorticoid receptor antagonist with anti-androgenic activity, has emerged as a candidate for drug repurposing in prostate cancer (PCa). Here, NR3C2 is linked to prostate carcinoma.